PT UBC Medical Indonesia Tbk (IDX:LABS)

IDX:LABS Statistics

Total Valuation

IDX:LABS has a market cap or net worth of IDR 568.80 billion. The enterprise value is 571.16 billion.

Market Cap	568.80B
Enterprise Value	571.16B

Important Dates

The next estimated earnings date is Thursday, April 9, 2026.

Earnings Date	Apr 9, 2026
Ex-Dividend Date	n/a

Share Statistics

IDX:LABS has 3.95 billion shares outstanding. The number of shares has increased by 67.78% in one year.

Current Share Class	3.95B
Shares Outstanding	3.95B
Shares Change (YoY)	+67.78%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	9.87%
Owned by Institutions (%)	n/a
Float	700.57M

Valuation Ratios

The trailing PE ratio is 61.15.

PE Ratio	61.15
Forward PE	n/a
PS Ratio	3.22
PB Ratio	3.77
P/TBV Ratio	3.89
P/FCF Ratio	34.45
P/OCF Ratio	29.85
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.48, with an EV/FCF ratio of 34.60.

EV / Earnings	61.40
EV / Sales	3.23
EV / EBITDA	20.48
EV / EBIT	38.27
EV / FCF	34.60

Financial Position

The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.18.

Current Ratio	2.85
Quick Ratio	1.07
Debt / Equity	0.18
Debt / EBITDA	0.99
Debt / FCF	1.66
Interest Coverage	8.54

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	7.77%
Return on Capital Employed (ROCE)	9.72%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	2.85B
Profits Per Employee	150.03M
Employee Count	62
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, IDX:LABS has paid 2.34 billion in taxes.

Income Tax	2.34B
Effective Tax Rate	20.08%

Stock Price Statistics

The stock price has increased by +12.70% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+12.70%
50-Day Moving Average	139.48
200-Day Moving Average	136.74
Relative Strength Index (RSI)	52.76
Average Volume (20 Days)	1,554,250

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, IDX:LABS had revenue of IDR 176.64 billion and earned 9.30 billion in profits. Earnings per share was 2.35.

Revenue	176.64B
Gross Profit	67.36B
Operating Income	14.92B
Pretax Income	11.64B
Net Income	9.30B
EBITDA	27.65B
EBIT	14.92B
Earnings Per Share (EPS)	2.35

Balance Sheet

The company has 25.11 billion in cash and 27.47 billion in debt, with a net cash position of -2.36 billion or -0.60 per share.

Cash & Cash Equivalents	25.11B
Total Debt	27.47B
Net Cash	-2.36B
Net Cash Per Share	-0.60
Equity (Book Value)	150.72B
Book Value Per Share	38.16
Working Capital	118.33B

Cash Flow

In the last 12 months, operating cash flow was 19.06 billion and capital expenditures -2.55 billion, giving a free cash flow of 16.51 billion.

Operating Cash Flow	19.06B
Capital Expenditures	-2.55B
Free Cash Flow	16.51B
FCF Per Share	4.18

Margins

Gross margin is 38.13%, with operating and profit margins of 8.45% and 5.27%.

Gross Margin	38.13%
Operating Margin	8.45%
Pretax Margin	6.59%
Profit Margin	5.27%
EBITDA Margin	15.65%
EBIT Margin	8.45%
FCF Margin	9.35%

Dividends & Yields

IDX:LABS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-67.78%
Shareholder Yield	-67.78%
Earnings Yield	1.64%
FCF Yield	2.90%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

IDX:LABS has an Altman Z-Score of 6.47 and a Piotroski F-Score of 5.

Altman Z-Score	6.47
Piotroski F-Score	5